Earnings ·
Disc Medicine reported second quarter 2026 financial results with a net loss of $59.5 million and R&D expenses of…
IRONDisc Medicine, Inc.
Disc Medicine reported second quarter 2026 financial results with a net loss of $59.5 million and R&D expenses of $46.9 million. The company ended the period with approximately $718 million in cash, providing operational runway into 2029. Clinically, Disc Medicine completed enrollment for the Phase 2 RESTORE-PV study of DISC-3405 in polycythemia vera and launched an Expanded Access Program for bitopertin in erythropoietic protoporphyria (EPP). The company aligned with the FDA that a successful Phase 3 APOLLO trial could support regulatory approval, with topline data expected in Q4 2026. Disc Medicine operates as a clinical-stage biopharmaceutical company focused on discovering and developing treatments for serious hematologic diseases.